![Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF](https://i1.rgstatic.net/publication/334653520_Hematogenous_Extramedullary_Relapse_in_Multiple_Myeloma_-_A_Multicenter_Retrospective_Study_in_127_Patients/links/619c9c8ed7d1af224b1a2622/largepreview.png)
Hematogenous Extramedullary Relapse in Multiple Myeloma – A Multicenter Retrospective Study in 127 Patients | Request PDF
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
![Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial - The Lancet Haematology Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/2085847190/2073944679/gr1.gif)
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial - The Lancet Haematology
![The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial - ScienceDirect The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S000649712102036X-gr1.jpg)
The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial - ScienceDirect
![Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies](https://www.mdpi.com/cancers/cancers-13-01712/article_deploy/html/images/cancers-13-01712-g001.png)
Cancers | Free Full-Text | Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies
Teva Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to Exten
![Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi - Luminari - 2018 - Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi - Luminari - 2018 -](https://onlinelibrary.wiley.com/cms/asset/4b7fa3a2-6447-42d7-b3ec-5e9f6ed37d99/hon.v36.1.cover.jpg?trick=1664184404982)
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi - Luminari - 2018 -
![PDF) Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study PDF) Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study](https://i1.rgstatic.net/publication/331767844_Filgrastim_prophylaxis_in_elderly_cancer_patients_in_the_real-life_setting_a_French_multicenter_observational_study_the_TULIP_study/links/5cb372ed299bf12097664df1/largepreview.png)
PDF) Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study
![Teva Secures European Approval of Trisenox for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia » FINCHANNEL Teva Secures European Approval of Trisenox for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia » FINCHANNEL](https://finchannel.com/wp-content/uploads/2016/11/heallthandbeauty_021trisenox.jpg)